SCHEMBL6283385

SCHEMBL6283385

CC(C)NC(=O)CNC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
FAAH O00519 1/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 3/20 0.38
CHRM5 P08912 1/20 0.36
CHRM3 P20309 1/20 0.36
KDM1A O60341 1/20 0.36
POLB P06746 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
LMNA P02545 1/20 0.34
CYP3A4 P08684 1/20 0.34
NFKB1 P19838 1/20 0.34
ADRA1A P35348 1/20 0.34
RAB9A P51151 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
DPP4 P27487 2/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24764542 0.81 MME (0.42) KMT2AMEN1FAAHTSHRRAB9A
SCHEMBL29459492 0.78 NPSR1 (0.44) MAPK1TSHRPOLBLMNAALDH1A1
SCHEMBL22917058 0.75 KMT2A (0.46) KMT2AMEN1FAAHMAPK1TSHR
SCHEMBL22859847 0.75 MAPK1 (0.39) MAPK1CA1CA2ALDH1A1
SCHEMBL24764848 0.75 ALDH1A1 (0.55) KMT2AMEN1LMNAALDH1A1
SCHEMBL24764840 0.75 ALDH1A1 (0.55) KMT2AMEN1LMNAALDH1A1
SCHEMBL6276761 0.74 PIK3CD (0.57) POLBDPP4DPP8DPP9ALDH1A1
SCHEMBL18999997 0.74 CYP2D6 (0.46) KMT2ALMNAMMP1MMP8ALDH1A1
SCHEMBL22059699 0.74 ALDH1A1 (0.37) KMT2AMEN1MAPK1LMNAMMP2
SCHEMBL22060164 0.74 ALDH1A1 (0.37) KMT2AMEN1LMNAMMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008358-B2 Synthesis of desosamines PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-05-18 US disclosed
US-20210115013-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-04-22 US disclosed
US-10947213-B1 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2021-03-16 US disclosed
US-20200347087-A1 SYNTHESIS OF DESOSAMINES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-11-05 US disclosed
US-20200316051-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2020-10-08 US disclosed
US-10696649-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2020-06-30 US disclosed
US-20200095222-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2020-03-26 US disclosed
US-10577374-B2 Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2020-03-03 US disclosed
US-10544182-B2 Synthesis of desosamines Presidents and Fellow of Harvard College (US) 2020-01-28 US disclosed
US-10399957-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2019-09-03 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-7812008-B2 9-substituted tetracyclines WYETH LLC (US) 2010-10-12 US disclosed
US-7812008-B2 9-substituted tetracyclines WYETH LLC (US) 2010-10-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-6841703-B2 Open chain alkoxyamine compounds and their use as polymerization regulators CIBA SPECIALTY CHEMICALS CORPORATION (US) 2005-01-11 US disclosed
EP-1100772-B1 OPEN CHAIN ALKOXYAMINE COMPOUNDS AND THEIR USE AS POLYMERIZATION REGULATORS CIBA SC HOLDING AG (CH) 2004-04-14 EP disclosed
US-20030125489-A1 Open chain alkoxyamine compounds and their use as polymerization regulators NESVADBA PETER (CH) 2003-07-03 US disclosed
US-6518326-B1 Open chain alkoxyamine compounds and their use as polymerization regulators CIBA SPECIALTY CHEMICALS CORPORATION 2003-02-11 US disclosed
EP-1100772-A1 OPEN CHAIN ALKOXYAMINE COMPOUNDS AND THEIR USE AS POLYMERIZATION REGULATORS Ciba SC Holding AG (CH) 2001-05-23 EP disclosed
WO-2000007981-A1 OPEN CHAIN ALKOXYAMINE COMPOUNDS AND THEIR USE AS POLYMERIZATION REGULATORS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008358-B2 Synthesis of desosamines NANS, GALE, FUT6 KMT2A 1390/4885MEN1 505/4885FAAH 3042/4885
US-20200316051-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 KMT2A 1879/4885MEN1 1719/4885FAAH 742/4885
US-10544182-B2 Synthesis of desosamines NANS, GALE, FUT6 KMT2A 1390/4885MEN1 505/4885FAAH 3042/4885
US-20210115013-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 KMT2A 1152/4885MEN1 4632/4885FAAH 2173/4885
US-20030125489-A1 Open chain alkoxyamine compounds and their use as polymerization regulators ALOX5, PTGER1, ALOX12 KMT2A 2491/4885MEN1 4480/4885FAAH 942/4885
US-10947213-B1 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 KMT2A 1063/4885MEN1 4517/4885FAAH 1883/4885
US-20200095222-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 KMT2A 1063/4885MEN1 4517/4885FAAH 1883/4885
US-20200347087-A1 SYNTHESIS OF DESOSAMINES NANS, GALE, FUT6 KMT2A 1390/4885MEN1 505/4885FAAH 3042/4885
US-10399957-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 KMT2A 1153/4885MEN1 4690/4885FAAH 1409/4885
US-10577374-B2 Bruton's tyrosine kinase inhibitors BTK, ABL1, SYK KMT2A 1481/4885MEN1 3176/4885FAAH 3972/4885
US-10696649-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 KMT2A 1063/4885MEN1 4517/4885FAAH 1883/4885
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 KMT2A 939/4885MEN1 2456/4885FAAH 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.